摘要
目的:探讨人参皂苷Rg1对异丙肾上腺素(ISO)诱导大鼠心肌肥厚的保护作用。方法:以异丙肾上腺素5 mg/(kg·d)腹腔注射制备大鼠心肌肥厚模型,实验分为:①正常组;②异丙肾上腺素组;③异丙肾上腺素+人参皂苷Rg1(1 mg/kg);④异丙肾上腺素+人参皂苷Rg1(2 mg/kg);⑤异丙肾上腺素+人参皂苷Rg1(4 mg/kg);⑥异丙肾上腺素+普萘洛尔组。给药组连续灌胃3周,并于灌胃1天后腹腔注射异丙肾上腺素2周,给药3周后,分别检测各组大鼠全心质量指数、左心室质量指数;取左心室组织进行HE染色,测量左心室心肌细胞横径;ELISA检测血清中TNF-α,IL-6水平;Western blot测定心肌组织中p65,IκBα表达。结果:同正常对照组相比,异丙肾上腺素组大鼠表现为全心质量指数和左心室质量指数显著增加,左心室心肌细胞横径增加,TNF-α,IL-6含量明显增加,p65表达增高而IκBα表达降低。与异丙肾上腺素组相比,人参皂苷Rg1(2、4 mg/kg)组全心质量指数和左心室质量指数和左心室心肌细胞横径不同程度降低,血清TNF-α,IL-6含量减少;p65表达降低而IκBα表达增高。结论:人参皂苷Rg1对异丙肾上腺素诱导的心肌肥厚有保护作用,这种保护作用可能与人参皂苷Rg1降低炎症反应,抑制NF-κB通路有关。
Objective: The aim of the present study wasto study the protective effect of Ginsenoside Bg1 on isoproterenol (Iso) induced myocardial hypertrophy. Methods: The isoproterenol 5 mg/(kg· d) was used as myocardial hypertrophy models by intraperltoneal injection. SD rats were randomly assigned to followingsix groups: (1)the control;(2)Iso group;(3)Iso + Ginsenoside Rgl ( 1 mg/kg) ;(4)Iso + Ginsenoside Rgl (2 mg/kg) ;(5)Ise + Ginsenosid'e Rgl (4 mg/kg) ;(6)Ise + Propranolol. Administered groups received continunally intragastric administration for 3 weeks, and Iso were intraperitoneal injected as long as 2 weeks in the day after that. 3 weeks later, Heart mass index (HMI) and left ventrlcular mass index (LVMI) in each group were measured;Hematoxyl/n-eosin(HE) staining were used for measuring transverse diameter of left ventricular myocardial cells(TDM) ; Western blot were used to quantify protein expression of IKBcL and p65 ;ELISA was performed to measure the level of TNF-α and IL-6. Results: Compared with the normal group, HMI, LVMI, TDM, the content of TNF-α and IL-6, and the expression of p65 were increased, while the expression of IKBct was decreased. Ginsenoside Rg1 (2,4 mg/kg) could obviously reduce the HMI, LVMI, TDM, the content of TNF-α and IL-6, and the expression of p65, increased the expression of IKBCt. Conclusion: Ginsenoside Rgl has a protective effect on Iso induced myocardial hypertrphy, which is partially via attenuating inflammatory effect and the NF-κB signling pathway.
出处
《中药药理与临床》
CAS
CSCD
北大核心
2014年第1期20-22,共3页
Pharmacology and Clinics of Chinese Materia Medica
基金
辽宁省自然科学基金(201102141)